Privia Health Group, Inc. (PRVA)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy limit 22.80 (GTC) on the pullback into the EMA21/SMA20/SMA200 confluence (22.76/22.76/22.66) after the 2026-11-05 earnings-driven advance; protective stop 22.03 sits below the 22.41 gap-fill low at the Change-A 1.0xATR floor; targets 24.34 (entry+2.0xATR) and 25.50 (entry+3.5xATR); R/R 2.00.
Company overview
Privia Health Group, Inc. partners with medical groups, health plans, and health systems to optimize physician practices and enhance patient experiences. It provides technology and administrative services to streamline workflows and improve care coordination, focusing on value-based care.
Fundamental
fairStrong growth and balance sheet contrast with thin margins and regulatory risks.
Net-cash, fast-growing physician-enablement platform: revenue +19.7% and GAAP operating income +73% in the first nine months of 2026, $446M of cash with no funded debt and a $250M undrawn revolver, offset by a 1.4% trailing net margin, roughly 87x trailing earnings, negative year-to-date operating cash flow from a receivables build, 62% of revenue concentrated in three payers, and an open OIG/DOJ healthcare inquiry. Verdict: mixed — improving operations and a fortress balance sheet against a rich earnings-based valuation and unquantified regulatory tail risk.
Sentiment
fairRecent positive catalysts have improved sentiment, though retail participation is unmeasurable.
Dominant drivers are the 2026-11-05 Q3 2026 results release (announced; revenue $657.0M with both lines beating estimates and FY2026 guidance raised) and the 2026-11-02 American Choice Healthcare MSSP acquisition (announced), with media polarity improving from a mildly negative baseline (polarity_score ≈ -0.06, n=3 aggregator-tier) to ≈ +0.35 in the 14-day scoring window — a determinate improvement of roughly +0.41 read off a thin two-item scored sample that is corroborated by an entirely constructively framed post-earnings headline cluster. Red-Flag Screen is clean, so no severe or moderate cap applies; the setup nonetheless sits in the mixed/forming band rather than the top band because both actionable catalysts are trailing (7 and 10 days old) and only partially priced, with no forward-dated driver inside 30 days.
Technical
goodThe stock is in a post-earnings uptrend with support at key moving averages.
PRVA is in a constructive post-earnings uptrend: price 23.67 sits above the SMA20 22.76, SMA50 21.32, SMA200 22.66, EMA9 23.52 and EMA21 22.76; ADX14 25.77 confirms a trending tape; MACD remains positive (line 0.74 > signal 0.59, histogram +0.15); RSI14 has cooled from 73.1 to 61.75 rather than broken down. The 2026-11-05 raise-guidance earnings day reset the base (Nov 4 close 22.40, Nov 5 gap to 23.93, low 22.41 gap-fill reversal, close 23.94), and the last three sessions are an orderly, declining-volume pullback from the 24.96 high (down-day volume 1.73M/0.82M/1.30M versus 2.81M/3.34M on the up days). Weak spots: MACD histogram is contracting (0.24 to 0.15) and the stock closed on its low, so the pullback can extend into the EMA21/SMA20/SMA200 confluence at 22.66-22.76 before the uptrend resumes — hence a limit into that confluence rather than a chase.
You’re looking at 2026-11-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

